ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,075.11
      -0.19%
      US Tech 100
      20,854.40
      -0.36%
      Dow Jones
      44,765.71
      -0.55%
      Brent Oil
      71.87
      -0.31%
      Bitcoin
      98,094.33
      1.05%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Rhythm Pharmaceuticals Inc (RYTM)

      7. Rhythm Pharmaceuticals Inc (RYTM) News

      Rhythm Pharmaceuticals Inc

      Rhythm Pharmaceuticals Inc (RYTM)

      NASDAQ
      57.82
      -2.55
      (-4.22%)
      Closed December 06 4:00PM
      Delayed by 15 minutes
      57.82
      0.05
      (0.09%)
      After Hours: 7:36PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      RYTM News

      Official News Only

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      November 13 2024
      RYTM (-4.22%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      November 13 2024
      RYTM (-4.22%)

      Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]
      Edgar (US Regulatory)
      November 13 2024
      RYTM (-4.22%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      November 12 2024
      RYTM (-4.22%)

      Form 4 - Statement of changes in beneficial ownership of securities
      Edgar (US Regulatory)
      November 08 2024
      RYTM (-4.22%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      November 07 2024
      RYTM (-4.22%)

      Form 144 - Report of proposed sale of securities
      Edgar (US Regulatory)
      November 06 2024
      RYTM (-4.22%)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]
      Edgar (US Regulatory)
      November 06 2024
      RYTM (-4.22%)

      Form 8-K - Current report
      Edgar (US Regulatory)
      November 05 2024
      RYTM (-4.22%)

      RYTM Discussion

      View Posts
      Monksdream Monksdream 1 month ago
      RYTM 10Q 11/5
      👍️0
      Monksdream Monksdream 3 months ago
      RYTM approaching a 52=week high
      👍️0
      Monksdream Monksdream 10 months ago
      RYTM new 52 week high
      👍️0
      Monksdream Monksdream 10 months ago
      RYTM new 52 week high

      👍️0
      Monksdream Monksdream 11 months ago
      RYTM new 52 week high
      👍️0
      Monksdream Monksdream 1 year ago
      RYTM new 52 week high
      👍️0
      midastouch017 midastouch017 2 years ago
      In my view ORMP is better than RYTM from investment perspective.

      Sigh, how wrong can one be!
      (including me - of course)
      👍️0
      bandit007 bandit007 2 years ago
      Why am I the only one posting here? This thing has been steady up over100% since I started posting here. Even on a day like today when most others are red. Another green day here!! $RYTM
      👍️0
      bandit007 bandit007 2 years ago
      When $20 breaks and holds this will fly! IMO
      👍️0
      bandit007 bandit007 2 years ago
      Looking like it’s ready to move up again here. Possible bounce off of support.
      👍️0
      Amatuer17 Amatuer17 2 years ago
      Some you win some you lose - I had a lot of conviction but later lost faith after that time and sold completely.
      👍️0
      Laszlo1 Laszlo1 2 years ago
      Sorry
      👍️0
      bandit007 bandit007 2 years ago
      Thanks for posting. Breakout mode! GL
      👍️0
      conix conix 2 years ago
      RYTM Chart

      👍️0
      bandit007 bandit007 2 years ago
      I’m liking the chart on this one.
      👍️0
      willlbone willlbone 2 years ago
      Two year slide continues.
      👍️0
      Amatuer17 Amatuer17 3 years ago
      I lost money on RYTM and booked losses already.
      👍️0
      midastouch017 midastouch017 3 years ago
      In my view ORMP is better than
      RYTM from investment perspective.

      Spot on!
      👍️0
      Amatuer17 Amatuer17 4 years ago
      In my view ORMP is better than RYTM from investment perspective.

      The current market capon $255 million allows it to be a 10 bagger ($2.55 B) - speciall that it has first in class product and huge unmet market.

      RTYM also has first in class product with unmet needs but it is rare disease and not many outside US can afford
      👍️0
      Amatuer17 Amatuer17 4 years ago
      Agree - it is good company
      Will take time to make money but proof of product is there.

      The valuation is fair at this point - upside maybe 50-70% by end of the year based on how they price and are able show sale.

      The payment cycle with insurance will be key as the product is very high priced -
      👍️0
      fishhunter fishhunter 4 years ago
      I started building a major position. And already a little green!
      Quite the biotech soon last couple weeks= opportunity!
      👍️0
      Amatuer17 Amatuer17 4 years ago
      For some reason it is tanking now -sale the news
      👍️0
      midastouch017 midastouch017 4 years ago
      RYTM is not cheap as it has market cap of $832 million for pre-revenue biotech - so it is richly valued.


      Are you kidding? You know what the mc is today?

      Market Cap 1.737B

      Since you introduced me to this company it has doubled
      in price, if it was richly valued then, what is it now?

      But this is besides my previous point - namely i 'missed'
      the entry point.
      👍️0
      Amatuer17 Amatuer17 4 years ago
      You can actually wait for some time and buy - this is a long term play
      👍️0
      midastouch017 midastouch017 4 years ago
      I missed out this one!

      👍️0
      Amatuer17 Amatuer17 4 years ago
      Just amazing results - they are starting new basket trials.

      The product is approved for one indication so it is now label expansion - the pricing power is amazing. This should really take off. Is it next Alexion in terms of rare disease treatment and pricing power?
      👍️0
      Amatuer17 Amatuer17 4 years ago
      Head the conf call - It was good call.

      The results are much better that what PR said. Slide 14-15 shows correct numbers which were clarified by them.

      Real numbers
      Total patients - 31
      Total BBS patients - 28
      No of patients dropped - 4
      Total no of patients relevant - 24

      No of patients with 5%+ weight reduction - 16 = 67% that is double the number compared to combined number of 34.5%

      No of patients who lost more than 10% weight - 11 out of 24 (45.8%)
      Mean reduction - 14.5%

      Compared to 1st approval which had few hundred population, BBS has 1000-1500 target population in US alone

      This is large population for rare disease - @ $200k per year - this is a big market.

      Also this is not a gene therapy - so drug is needed forever and it keeps the weight down.

      Last point - All genes targeted in basket trial are in BBS category (strong or very strong relationship) so they think the basket trial results may be positive.

      Cash enough till 2022. I think if stock goes down further, it will be good opportunity to buy - stock could give 50% returns from here in 6 months based on basket trial results.
      👍️0
      Amatuer17 Amatuer17 4 years ago
      Phase 3 results - BBS stat significant -AL not

      Market reaction is not good. Conf call will give more info

      https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-positive-topline-120000038.html
      👍️0
      Amatuer17 Amatuer17 4 years ago
      Finally - Approval

      “Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE™(setmelanotide) as First-ever Therapy for Chronic Weight Management in Patients with Obesity Due to POMC, PCSK1 or LEPR Deficiency”

      Another good news - voucher that they can sell or use for next approval

      “With this approval, the FDA issued a Rare Pediatric Disease Priority Review Voucher (PRV) to Rhythm. The PRV can be redeemed to receive priority review for any subsequent marketing application or sold or transferred to other companies for their programs.”


      https://finance.yahoo.com/news/rhythm-pharmaceuticals-announces-fda-approval-123000486.html
      👍️0
      grich1 grich1 4 years ago
      That’s a big run with PDUFA being in November. I took some profit but still in the game and will buy 100% back if reversal. Outstanding shares only @ 44M and float 30M. PT @ $33.
      👍️0
      midastouch017 midastouch017 4 years ago
      Good call!

      👍️0
      Amatuer17 Amatuer17 4 years ago
      What is happening? Looks good
      👍️0
      midastouch017 midastouch017 4 years ago
      Not so sure the last few years.

      I am no US citizen, i would not like to comment
      about US politics. We have enough political
      unrest in my part of the globe, in Israel.

      I’ve done enough DD on PSTI and RDHL

      I was a heavy investor in PSTI, sold it all a few
      weeks ago at a big loss, and not looking back.

      RDHL, otoh is a serious company, i am sure it will
      go places, high places that is.

      As for RYTM, I have no funds at the moment, but
      will start a position soon.

      GLTY
      👍️0
      Amatuer17 Amatuer17 4 years ago
      RYTM is not cheap as it has market cap of $832 million for pre-revenue biotech - so it is richly valued.

      It has 70 employees - more than many biotech at this stage but not sufficient for marketing the drug. So they have to find a partner or go with buyout.

      The good news is - the co has $228 milllion plus cash and it will allow them to run till end of 2021.

      They are in niche area and there is no other competition nearby. If the drug can address genetic obesity - they have 80,000 target audience in US alone.

      If the drug can be tested on genetic obesity/weight loss, it will be gold mine.
      👍️0
      pennyrich pennyrich 4 years ago
      Not so sure the last few years. But what the heck.
      I’m new on RYTM. I’ve done enough DD on PSTI and RDHL to hold a small 500 share stake in both. I’ll do some extra digging here because the stakes are much higher. The last 3 months haven’t been bad on the other two.
      GLTUA
      Pr
      👍️0
      midastouch017 midastouch017 4 years ago
      Sure. A free country, isn't it?

      👍️0
      pennyrich pennyrich 4 years ago
      Can anyone play???
      👍️0
      midastouch017 midastouch017 4 years ago
      Thanks for the heads up Amatuer17,
      i'll dig into it over the weekend.

      👍️0
      Amatuer17 Amatuer17 4 years ago
      Welcome to the board. Hope we all make money

      This is a PDUFA based play

      PDUFA date - 27th Nov

      Disease - rare disease - obesity based on genetics

      MOA - impacts the MC4PA gene that controls obesity and hunger. They have 4 more trials for other sub areas also in advance stage.

      As per conf call - they are looking at pricing from $200k to $400k per year Patient population for this approval - around 1000

      https://ir.rhythmtx.com/static-files/fd4e0919-4d82-47e0-afe3-8cd9b5151490
      👍️0

      Your Recent History

      NASDAQ
      RYTM
      Rhythm Pharmaceuticals
      Delayed Upgrade Clock